Aspen Pharma sees revenue spike, plans to buy GSK Site

By Zachary Brennan

- Last updated on GMT

Aspen to buy GSK manufacturing site
Aspen to buy GSK manufacturing site

Related tags Russia Pharmacology Aspen

Aspen Pharma saw its revenue increase over the past year by almost 30% and is now looking to further expand its manufacturing capabilities.

Aspen revealed in its earnings that it has submitted a binding, irrevocable offer to GSK to acquire its specialised sterile production site for Arixtra and Fraxiparine/Fraxodi brands worldwide (excluding China, India and Pakistan), as well as the brands themselves for about £700m ($1.1bn). According to the terms of the offer, Aspen would acquire the Notre Dame de Bondeville, France-based site on April 30, 2014.

GSK in May announced that Aspen​ and other CMOs would pick up some of the slack as it was closing its Australian tablet packaging site.

The South African-based company now has manufacturing sites in Australia, Brazil, Germany, Mexico and two in South Africa.

MSD Deal

Aspen also acquired Merck’s API manufacturing business​ in July, primarily located in the Netherlands, for approximately €36m plus the value of inventory, which Aspen now says will be effective on Oct. 1. 

An Aspen spokesman previously told us that the plants will support its contract manufacturing for Asian and Latin American clients. That work will be bolstered by a newly established subsidiary in Malaysia that commenced trade in July, while another subsidiary was created in Taiwan.

In a related agreement with MSD, Aspen has an option to acquire 11 branded finished dose form molecules covering a range of therapeutic areas for approximately $600m.

The MSD and GSK deals are expected to enable Aspen to establish business units in Russia, other former Soviet republics and across Europe, according to the company’s filing.

South Africa

Aspen also announced expansion projects at all of its local South African sites. After acquiring land adjacent to its Port Elizabeth site, Aspen is building a high containment suite and upgrading its packaging capabilities there.

The expansion and enhancement of manufacturing capabilities in its fine chemicals division is also picking up to integrate with the company’s API (active pharmaceutical ingredient) demand.  Projects underway in East London and at Clayville are nearing completion, the company said.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us